Vigil Neuroscience to Present at Stifel 2023 CNS Days
Vigil Neuroscience (Nasdaq: VIGL) announced that Ivana Magovčević-Liebisch, Ph.D., J.D., its CEO, will participate in a fireside chat at the Stifel 2023 CNS Days virtual conference on March 29, 2023, at 12:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vigil Neuroscience (Nasdaq: VIGL) announced that Ivana Magovčević-Liebisch, Ph.D., J.D., its CEO, will participate in a fireside chat at the Stifel 2023 CNS Days virtual conference on March 29, 2023, at 12:00 p.m. ET. Investors can access the live webcast through the 'Events & Presentations' section on the company's website, with an archived replay available for 90 days post-event.
The company focuses on developing treatments for neurodegenerative diseases using microglia. Its lead candidate, VGL101, is in a Phase 2 trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), and it is also exploring treatments for Alzheimer's disease.
Details
News Market Reaction – VIGL
The recorded move for VIGL in the trading session of this news was +10.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 CNS Days virtual conference on Wednesday, March 29, 2023, at 12:00 p.m. ET.
To access a live webcast of this presentation, please visit “Events & Presentations” in the “Investors” section of the Vigil website at www.vigilneuro.com. An archived replay will be available for approximately 90 days following the presentation.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the 'Investors' section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.